N

NuVasive Inc
F:NK8

Watchlist Manager
NuVasive Inc
F:NK8
Watchlist
Price: 36.8 EUR Market Closed
Market Cap: 1.9B EUR
Have any thoughts about
NuVasive Inc?
Write Note

Intrinsic Value

The intrinsic value of one NK8 stock under the Base Case scenario is 28.26 EUR. Compared to the current market price of 36.8 EUR, NuVasive Inc is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NK8 Intrinsic Value
28.26 EUR
Overvaluation 23%
Intrinsic Value
Price
N
Worst Case
Base Case
Best Case

Valuation Backtest
NuVasive Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NK8 cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NK8?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about NuVasive Inc

Provide an overview of the primary business activities
of NuVasive Inc.

What unique competitive advantages
does NuVasive Inc hold over its rivals?

What risks and challenges
does NuVasive Inc face in the near future?

Summarize the latest earnings call
of NuVasive Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for NuVasive Inc.

Provide P/S
for NuVasive Inc.

Provide P/E
for NuVasive Inc.

Provide P/OCF
for NuVasive Inc.

Provide P/FCFE
for NuVasive Inc.

Provide P/B
for NuVasive Inc.

Provide EV/S
for NuVasive Inc.

Provide EV/GP
for NuVasive Inc.

Provide EV/EBITDA
for NuVasive Inc.

Provide EV/EBIT
for NuVasive Inc.

Provide EV/OCF
for NuVasive Inc.

Provide EV/FCFF
for NuVasive Inc.

Provide EV/IC
for NuVasive Inc.

Show me price targets
for NuVasive Inc made by professional analysts.

What are the Revenue projections
for NuVasive Inc?

How accurate were the past Revenue estimates
for NuVasive Inc?

What are the Net Income projections
for NuVasive Inc?

How accurate were the past Net Income estimates
for NuVasive Inc?

What are the EPS projections
for NuVasive Inc?

How accurate were the past EPS estimates
for NuVasive Inc?

What are the EBIT projections
for NuVasive Inc?

How accurate were the past EBIT estimates
for NuVasive Inc?

Compare the revenue forecasts
for NuVasive Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of NuVasive Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of NuVasive Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of NuVasive Inc compared to its peers.

Compare the P/E ratios
of NuVasive Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing NuVasive Inc with its peers.

Analyze the financial leverage
of NuVasive Inc compared to its main competitors.

Show all profitability ratios
for NuVasive Inc.

Provide ROE
for NuVasive Inc.

Provide ROA
for NuVasive Inc.

Provide ROIC
for NuVasive Inc.

Provide ROCE
for NuVasive Inc.

Provide Gross Margin
for NuVasive Inc.

Provide Operating Margin
for NuVasive Inc.

Provide Net Margin
for NuVasive Inc.

Provide FCF Margin
for NuVasive Inc.

Show all solvency ratios
for NuVasive Inc.

Provide D/E Ratio
for NuVasive Inc.

Provide D/A Ratio
for NuVasive Inc.

Provide Interest Coverage Ratio
for NuVasive Inc.

Provide Altman Z-Score Ratio
for NuVasive Inc.

Provide Quick Ratio
for NuVasive Inc.

Provide Current Ratio
for NuVasive Inc.

Provide Cash Ratio
for NuVasive Inc.

What is the historical Revenue growth
over the last 5 years for NuVasive Inc?

What is the historical Net Income growth
over the last 5 years for NuVasive Inc?

What is the current Free Cash Flow
of NuVasive Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for NuVasive Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
NuVasive Inc

Current Assets 728.3m
Cash & Short-Term Investments 80.7m
Receivables 267.1m
Other Current Assets 380.4m
Non-Current Assets 1.4B
PP&E 452.6m
Intangibles 808.3m
Other Non-Current Assets 100.4m
Current Liabilities 582.6m
Accounts Payable 118.8m
Accrued Liabilities 60.7m
Short-Term Debt 350m
Other Current Liabilities 53.1m
Non-Current Liabilities 614.4m
Long-Term Debt 446.4m
Other Non-Current Liabilities 168m
Efficiency

Earnings Waterfall
NuVasive Inc

Revenue
1.2B USD
Cost of Revenue
-347.5m USD
Gross Profit
878.7m USD
Operating Expenses
-796.2m USD
Operating Income
82.6m USD
Other Expenses
-54.1m USD
Net Income
28.5m USD

Free Cash Flow Analysis
NuVasive Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

NuVasive reported a 2.4% increase in net sales to $317.8 million in the second quarter of 2023. U.S. Cervical business continued to flourish with over 20% growth, albeit against the backdrop of a 9.3% drop in surgical support sales, with non-GAAP gross margin dipping slightly to 71.8%. Despite a competitive market due to merger activities, they maintained solid performance, especially in the U.S. and international core spine segments. Free cash flow declined to $3 million from the previous year's $26 million, attributed to reduced operating cash flow. The earnings outlook remains steady, predicting 6% to 8% growth in net sales for fiscal year 2023, assuming constant currency rates.

What is Earnings Call?
Fundamental Scores

NK8 Profitability Score
Profitability Due Diligence

NuVasive Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Negative Free Cash Flow
ROE is Increasing
Positive 3-Years Revenue Growth
48/100
Profitability
Score

NuVasive Inc's profitability score is 48/100. The higher the profitability score, the more profitable the company is.

NK8 Solvency Score
Solvency Due Diligence

NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Average Altman Z-Score
46/100
Solvency
Score

NuVasive Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NK8 Price Targets Summary
NuVasive Inc

There are no price targets for NK8.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NK8?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for NK8 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

NuVasive Inc

Country

United States of America

Industry

Health Care

Market Cap

1.9B EUR

Dividend Yield

0%

Description

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. The company is headquartered in San Diego, California and currently employs 2,900 full-time employees. The company went IPO on 2004-05-13. The firm offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics and enabling technologies, as well as systems and services for intraoperative neuromonitoring. In addition, it develops and sells magnetically adjustable implant systems for spine and specialized orthopedic procedures. In addition, it also designs and sells expandable growing rod implant systems for the treatment of early-onset scoliosis, which can be non-invasively lengthened implantation with precise, incremental adjustments via an external remote controller using magnetic technology called MAGnetic External Control (MAGEC).

Contact

CALIFORNIA
San Diego
7475 Lusk Blvd
+18589091800.0
www.nuvasive.com

IPO

2004-05-13

Employees

2 900

Officers

CEO & Director
Mr. J. Christopher Barry
Exec. VP & CFO
Mr. Matthew K. Harbaugh
Sr. VP of Global Operations
Mr. Dale A. Wolf
Sr. VP, Gen. Counsel & Corp. Sec.
Mr. Nathaniel B. Sisitsky Esq.
VP, Corp. Controller & Chief Accounting Officer
Mr. Marc Rosenbaum
Sr. VP & Chief Technology Officer
Mr. Ryan Donahoe
Show More
Chief Information Officer
Mr. Johnson Lai
VP of Investor Relations
Ms. Juliet C. Cunningham
Sr. VP of People & Culture
Mr. Michael Farrington
Sr. VP of Strategy & Corp. Devel.
Mr. Sean Freeman
Show Less

See Also

Discover More
What is the Intrinsic Value of one NK8 stock?

The intrinsic value of one NK8 stock under the Base Case scenario is 28.26 EUR.

Is NK8 stock undervalued or overvalued?

Compared to the current market price of 36.8 EUR, NuVasive Inc is Overvalued by 23%.

Back to Top